ALPINE IMMUNE SCIENCES, INC.: 10-Q filed 2016-05-03
What ALPINE IMMUNE SCIENCES, INC. reported in its quarterly report filed 2016-05-03 (fiscal Q1 2016): 20 published measures, 42 facts as tagged in accession 0001558370-16-005215.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-05-03
- Fiscal period
- fiscal Q1 2016
- Accession
- 0001558370-16-005215 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ALPINE IMMUNE SCIENCES, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 80,937,000 | USD | |
| At 2015-12-31 | 87,909,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 76,359,000 | USD | |
| At 2015-12-31 | 83,490,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 16,030,000 | USD | |
| At 2015-12-31 | 24,991,000 | USD | |
| At 2015-03-31 | 22,865,000 | USD | |
| At 2014-12-31 | 27,812,000 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 31,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 52,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | -156,675,000 | USD | |
| At 2015-12-31 | -148,837,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 707,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 151,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -7,934,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -4,315,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 80,713,000 | USD | |
| At 2015-12-31 | 87,686,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 4,578,000 | USD | |
| At 2015-12-31 | 4,419,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 1,196,000 | USD | |
| At 2015-12-31 | 994,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 5,567,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 3,017,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 15,462,030 | shares | |
| At 2015-12-31 | 15,462,030 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 3,000 | USD | |
| At 2015-12-31 | 3,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 76,359,000 | USD | |
| At 2015-12-31 | 83,490,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 501,000 | USD | |
| At 2015-12-31 | 432,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -7,838,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -4,314,000 | USD | 90 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -7,838,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -4,314,000 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 2,367,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 1,298,000 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 30,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 16,000 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 202,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 1,709,000 | USD | 90 |
Inspect the source
- Entity
- ALPINE IMMUNE SCIENCES, INC. / CIK 0001626199
- Captured
- SEC response SHA-256
2a7df7fe63b5c267fe0cf9bef64742a505c8e4128001c3125621653d2bc29fc2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001626199.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))